<DOC>
	<DOCNO>NCT01359462</DOCNO>
	<brief_summary>For hepatic cirrhosis subject ascites low extremity , study Pharmacokinetics , pharmacology , safety drug fast condition .</brief_summary>
	<brief_title>Multiple-dose Pharmacokinetics Study Tolvaptan Tablets Chinese Patients With Hepatocirrhosis</brief_title>
	<detailed_description>This study evaluate multiple-dose pharmacokinetics , pharmacological action safety Tolvaptan tablet administer orally ( 15 mg daily ) consecutively 7 day Chinese adult patient confirm Child-Pugh Class B（score 7-9） hepatocirrhosis ( accompany ascites ) . Trial Design : 1 . Open , single-center , multi-dose pharmacokinetics study 2 . Study population : Chinese adult patient confirm Child-Pugh Class B ( score 7-9 ) hepatocirrhosis ( accompany ascites ) 3 . Dosage mode administration investigational product : Oral administration 1 tablet ( 15mg ) daily , consecutive 7 day start day 1 treatment . 4 . Study duration : Screening : 14 day maximum ; Treatment ( ) : 7 day ; Observation : 1 day</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Hepatic Cirrhosis ascites low extremity edema 2 . Hospitalized patient 3 . 18 year old~75 year old 4 . Inform Consent Form Signed 1 . Patients follow disease , complication symptom : Hepatic encephalopathy ( coma degree classification note 1 Grade 2 ) ; Malignant ascites ; Spontaneous bacterial peritonitis ; Likely gastrointestinal bleeding study period ; Heart failure ( NYHA Note 2 Class Ⅲ andⅣ ) ; Anuria ( daily urine output 100mL ) ; Dysuria induce urinary tract stenosis , calculus , tumor . 2 . Patients follow history : With gastrointestinal bleeding within 10 day prior screen ; With cerebrovascular accident within 1 month prior screen ; With gout attack within 1 month prior screen ; With allergy atopy benzodiazepine drug ( benazepril hydrochloride , etc. ) . 3 . Patients whose systolic blood pressure 90mmHg screening ; 4 . Patients abnormal value follow lab examination indicator : Serum creatinine high 2.5 time upper limit normal range , serum Na+ &gt; 145mmol/L ( high upper limit normal range ) , serum K+ &gt; 5.5 mmol/L , uric acid &gt; 476µmol/L , childPugh score &gt; 10 5 . Patients ineligible oral medication 6 . Patients pregnancy lactation ; female childbearing potential take contraceptive measure ; 7 . Patients take blood product include albumin product within 4 day prior application investigational product ; 8 . Patients participate clinical trial drug within 1 month prior screen ; 9 . Patients used participate clinical trial Tolvaptan take say drug ; 10 . Patients determine investigator illegible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>hepatic cirrhosis patient ascites</keyword>
</DOC>